MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), announced today that a U.S. Food and Drug Administration (FDA) Advisory Panel will review the Premarket Approval (PMA) application for the company’s Endeavor® Drug Eluting Coronary Stent on October 10. The FDA’s Circulatory System Devices Panel is scheduled to meet October 10 and 11. Endeavor is the only drug eluting stent on the agenda for review during the October 10 panel meeting.
